AUTHOR=Zendejas-Hernandez Ulises , Alcántara-Martínez Nemi , Vivar Diana Tovar , Valenzuela Fermín , Sosa Espinoza Alejandro , Cervera Ceballos Eduardo Emir 

TITLE=Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial

JOURNAL=Frontiers in Immunology

VOLUME=Volume 14 - 2023

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1282280

DOI=10.3389/fimmu.2023.1282280

ISSN=1664-3224

ABSTRACT=Glycyrrhizin (GA) and its derivative Enoxolone (18β), isolated from the Glycyrrhiza glabra plant, are two potential molecules for treating viral diseases. Both demonstrate to regulate immune system with antiviral and anti-inflammatory activities, with the latter mainly due to modulation of inflammatory cytokines. The aim of this clinical trial was to evaluate the safety and efficacy of a nebulized GA/18β drug for treating  patients. An open label, randomized, placebocontrolled clinical trial was conducted in Mexico City from January-August 2022 (Registration No. PROTAP-CLI-00). Clinical and biochemical parameters were recorded. Blood samples from patients were regularly collected to evaluate interleukins